Publicaciones en colaboración con investigadores/as de University of Texas MD Anderson Cancer Center (10)

2024

  1. A Phase Ib/II Randomized Clinical Trial of Oleclumab with or without Durvalumab plus Chemotherapy in Patients with Metastatic Pancreatic Ductal Adenocarcinoma

    Clinical Cancer Research, Vol. 30, Núm. 20, pp. 4609-4617

2022

  1. Identifying FGFR2 fusions/rearrangements in cholangiocarcinoma patients using a novel cfDNA algorithm for treatment with RLY-4008, a highly selective irreversible FGFR2 inhibitor

    European Journal of Cancer, Vol. 174, pp. S116

2021

  1. Elevated NSD3 histone methylation activity drives squamous cell lung cancer

    Nature, Vol. 590, Núm. 7846, pp. 504-508

2020

  1. The Mir181ab1 cluster promotes KRAS-driven oncogenesis and progression in lung and pancreas

    Journal of Clinical Investigation, Vol. 130, Núm. 4, pp. 1879-1895

2019

  1. Inhibitor of differentiation-1 sustains mutant KRAS-driven progression, maintenance, and metastasis of lung adenocarcinoma via regulation of a FOSL1 network

    Cancer Research, Vol. 79, Núm. 3, pp. 625-638

2015

  1. Proteasome inhibition enhances the killing effect of BikDD gene therapy

    American Journal of Translational Research, Vol. 7, Núm. 2, pp. 319-327

2014

  1. RHOB influences lung adenocarcinoma metastasis and resistance in a host-sensitive manner

    Molecular Oncology, Vol. 8, Núm. 2, pp. 196-206

  2. S6k1 promotes invasiveness of breast cancer cells in a model of metastasis of triple-negative breast cancer

    American Journal of Translational Research, Vol. 6, Núm. 4, pp. 361-376

2011

  1. Inhibitor of differentiation-1 as a novel prognostic factor in NSCLC patients with adenocarcinoma histology and its potential contribution to therapy resistance

    Clinical Cancer Research, Vol. 17, Núm. 12, pp. 4155-4166

2010

  1. Wilms tumor 1 (WT1) regulates KRAS-driven oncogenesis and senescence in mouse and human models

    Journal of Clinical Investigation, Vol. 120, Núm. 11, pp. 3940-3952